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Abstract: Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the 
US Food and Drug Administration for the treatment of patients with metastatic colorectal can-
cer. Since this time, however, few case reports outlining real-world usage have been published 
in the literature. Here, we detail the clinical history of an elderly woman with KRAS wild-type 
colon cancer who received regorafenib after prior treatment with other agents. We show that 
by employing dose modification strategies to address adverse events, this patient was able to 
remain on therapy for 11 months and achieve stable disease.
Keywords: regorafenib, metastatic colorectal cancer, oral multikinase inhibitor
Introduction
Colorectal cancer (CRC) is one of most common cancers and leading causes 
of mortality in the USA, accounting for approximately 136,000 new cases and 
50,000 deaths per year.1 For metastatic or unresectable CRC, standard first- and sec-
ond-line  treatments  typically involve a combination of cytotoxic chemotherapies (eg, 
 FOLFIRI [5- fluorouracil + oxaliplatin + irinotecan])2,3 and molecular targeted agents 
(eg, bevacizumab,  cetuximab, panitumumab),4–6 which can help to improve progression-
free survival and overall survival. However, due to the nature of the  disease, many 
patients will progress through guideline-recommended standard regimens while main-
taining a good performance status. Regorafenib, an oral multikinase inhibitor, which 
targets angiogenic, stromal, and oncogenic receptor tyrosine kinases, was approved 
by the US Food and Drug Administration in 2012 for the treatment of patients with 
metastatic CRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, 
and irinotecan-based chemotherapy, an anti–vascular endothelial growth factor (VEGF) 
therapy and, if KRAS wild-type, an anti–epidermal growth factor receptor (EGFR) 
therapy.7 This approval was based on the CORRECT study, which demonstrated a 
median overall survival of 6.4 months with regorafenib vs 5.0 months with placebo 
(hazard ratio, 0.77; 95% confidence interval, 0.64–0.94; P=0.0052).8 Among the most 
common adverse effects were fatigue, hand–foot skin reaction, diarrhea, hypertension, 
and rash. Here, a case of an elderly patient on regorafenib who achieved stable disease 
for over 11 months with strategic dose modifications was presented.
Case report
The following report describes a patient with metastatic CRC who was treated with 
regorafenib. No ethics approval was needed for the care of this patient as all treatments 
were in accordance with institutional best practices. Verbal consent to appear in this 
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case study was given by the patient to Dr Seery. A 73-year-old 
Indian female with a past medical history of hypertension 
and hyper cholesterolemia was diagnosed in September 2010 
with left-sided adenocarcinoma of the colon. The patient had 
no history of smoking, alcohol consumption, or any  family 
history of cancer. The patient initially had symptoms of 
hemoptysis for approximately 2 weeks and then subsequently 
developed hematochezia for 3 days. Due to these symptoms, 
the patient underwent a colonoscopy, which revealed left-
sided colon cancer. A left hemicolectomy was performed; 
pathology revealed a stage IIIB well-differentiated, KRAS 
wild-type adenocarcinoma, with one out of 15 lymph nodes 
testing positive. The patient moved back to India and did not 
receive adjuvant chemotherapy due to patient preference.
In March 2011, the patient returned to the USA with com-
plaints of mild abdominal distention, and a subsequent posi-
tron emission tomography/computed tomography (PET/CT) 
scan showed evidence of recurrence, with ovarian and peri-
toneal metastases. A biopsy was performed, which revealed 
CK20 positivity, consistent with colonic adenocarcinoma. 
The patient began treatment with capecitabine, oxaliplatin, 
and bevacizumab, and developed an anaphylactic reaction 
in the sixth cycle. She continued with single-agent capecit-
abine for an additional two cycles and completed therapy 
in June 2011 as there was no further evidence of disease on 
the PET/CT scans.
The patient did not receive any additional therapy until 
early 2012 when she was restaged and was again noted to have 
diffuse metastatic disease in the peritoneum, with imaging 
consistent with moderate to extensive carcinomatosis. The 
patient received cetuximab and FOLFIRI from February 2012 
through August 2012 and achieved an excellent response, 
with the PET/CT scan showing no evidence of measurable 
disease, with some minimal hypodensities in the liver that 
were not PET avid. Therapy was discontinued at that time as 
the patient preferred an active surveillance approach.
The patient did well until April 2013 when she experi-
enced increased abdominal distention, bloating, and difficulty 
with defecation. The patient received a repeat CT scan that 
showed progression of the disease, with a large pleural-
based mass in the right lower lobe with bilateral pleural 
effusions, ascites, and multiple peritoneal implants, as well 
as omental infiltration along with a possible L3 lytic lesion. 
Also, the patient’s carcinoembryonic antigen (CEA) values 
had increased to 23. As a result, the patient was restarted 
on cetuximab and FOLFIRI in May 2013; however, a PET/
CT scan 2 months later revealed a mixed response, with 
persistent fluorodeoxyglucose-avid right pleural disease, 
but also some areas of decreased activity with stable nodal 
disease in the left axilla, retroperitoneum, and pelvis, and 
increased activity in the left inguinal and right retrocrural 
nodes. There was also resolution of pleural effusion and 
ascites. The patient continued with cetuximab and FOLFIRI 
until August 2013, and a repeat PET/CT scan in September 
2013 revealed progressive disease in the right pleural mass 
along with increase in size of the retrocrural and left inguinal 
lymph nodes and liver (Figure 1A). The patient’s CEA was 
8.3 in October 2013.
The patient was started on regorafenib 160 mg daily on 
September 12, 2013, but required a treatment interruption 
due to hypertension with consistent systolic blood pressure 
readings in the range of 170 mm Hg and diastolic blood pres-
sure in the range of 100 mm Hg, as well as Grade 3 fatigue 
during cycle 1. The patient was started on antihypertensive 
medications, and regorafenib was held for 2 weeks to resolve 
these adverse events. After this treatment interruption, rego-
rafenib was restarted at a dose of 120 mg. The dose was then 
Figure 1 pet/Ct scans prior to and during regorafenib treatment.
Notes: (A) abdominal pet scan before initiation of regorafenib, with right pleural-
based mass (green box) measuring 27.6 mm, 14.4 max standardized uptake value 
(sUV); (B) five months after therapy, with same right pleural-based mass (green 
box) measuring 26.7 mm, 3.4 max sUV.
Abbreviations: pet, positron emission tomography; Ct, computed tomography.
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reduced again due to Grade 3 fatigue, and the patient’s dose 
was stabilized at 80 mg daily.
A repeat PET/CT scan in February 2014 showed a mixed 
response, with increased activity in non-target lesions noted 
in multiple omental, peritoneal, and pelvic lesions, but 
decreased activity in target lesions, specifically the thoracic 
and liver lesions, with new activity in the right tenth rib (Figure 
1B). Specifically, a right pleural-based mass had decreased 
from 27.6 mm to 26.7 mm, and standardized uptake value 
decreased from 14.4 to 3.4 in conjunction with a decrease in 
disease measuring from 58.0 mm to 43.6 mm in the central 
pelvic mesentery superior extending to the uterine fundus. 
The patient’s CEA decreased to 3.7, while Eastern Coopera-
tive Oncology Group (ECOG) performance status improved 
from 2 to 1, and treatment was therefore continued at 80 
mg daily. The patient’s most recent PET/CT scan in August 
2014 showed frank progression of disease, with an increase 
in number and activity of multiple metastatic pulmonary and 
hepatic lesions along with increased activity in omental and 
mesenteric implants. As of August 2015, the patient has been 
on regorafenib for 11 months with progression; however, her 
ECOG performance status remains at 1, and she would like to 
continue taking the medication as she does not have any side 
effects and feels her quality of life has improved.
Ethics
Verbal consent was obtained from the patient prior to her depart-
ing our facility for hospice care. The patient’s identification has 
been protected and any information which could potentially be 
used to reveal the identity of the patient has been removed.
Conclusion
We reported on a case of an elderly woman with KRAS wild-
type, refractory metastatic colon cancer who has received 
multiple chemotherapy regimens, most recently regorafenib 
for 11 months with minimal side effects and palliation of 
symptoms. The report shows that regorafenib can provide a 
decrease in tumor burden and improve quality of life with 
prolonged survival if an appropriate dose is used in terms of 
balancing side effects with benefits of symptom palliation. 
Moreover, the report shows that continuing therapy beyond 
disease progression is no longer an absolute contraindica-
tion. This case report additionally demonstrates that close 
and frequent follow-ups by the primary oncologist is needed 
in order to monitor side effects and to find the effective 
and tolerable dose. In the CORRECT study, the frequency 
of adverse events was shown to peak during the first cycle 
and gradually taper off with subsequent cycles.8 This report 
suggests that regorafenib can be a viable option for patients 
who still have a good performance status and have progressed 
through other regimens. Importantly, patient and financial 
support services are in place through the REACH program 
to help patients manage the cost of this therapy.
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